In a routine setting, patients usually undergo evaluation of single variants at each instance for therapy selection, e.g., in NSCLC, evaluation of EGFR mutations, ALK-fusions, PD-L1 and MMR status are usually not performed simultaneously which leads to extended time to treatment. The gene discussed is ALK; the disease is non-small cell lung carcinoma.